TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A TGFβ SIGNALING INHIBITOR Application WO-2022090439-A1 World Intellectual Property Organisation (WIPO) 05 May 2022
TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOR Application WO-2020208124-A1 World Intellectual Property Organisation (WIPO) 15 Oct 2020